- Home
- HLP vs CRVO Comparison
HLP vs CRVO Comparison
Compare HLP & CRVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HLP | CRVO |
|---|---|---|
| Founded | 2021 | 2001 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 102.1M | 89.1M |
| IPO Year | 2023 | N/A |
Fundamental Metrics
Financial Performance| Metric | HLP | CRVO |
|---|---|---|
| Price | $1.47 | $8.80 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $21.50 |
| AVG Volume (30 Days) | ★ 88.4K | 86.6K |
| Earning Date | 05-15-2026 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $16,731,357.00 | $6,159,786.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $69.15 | ★ N/A |
| Revenue Growth | ★ 19.13 | N/A |
| 52 Week Low | $0.61 | $1.80 |
| 52 Week High | $1.82 | $16.94 |
Technical Indicators
Market Signals| Indicator | HLP | CRVO |
|---|---|---|
| Relative Strength Index (RSI) | 42.34 | 53.05 |
| Support Level | $1.48 | $7.80 |
| Resistance Level | $1.65 | $10.00 |
| Average True Range (ATR) | 0.12 | 0.75 |
| MACD | -0.02 | -0.02 |
| Stochastic Oscillator | 14.26 | 47.39 |
Price Performance
Historical ComparisonAbout HLP Hongli Group Inc.
Hongli Group Inc is a cold roll-formed steel profile manufacturer in China. It customizes and manufactures cold roll-formed steel profiles for machinery and equipment in a variety of sectors, including but not limited to mining and excavation, construction, agriculture, and transportation. Geographically, the company generates the majority of its revenue from the PRC.
About CRVO CervoMed Inc.
CervoMed Inc is a clinical stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.